Bio-Techne

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Bio-Techne and other ETFs, options, and stocks.

About TECH

Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. Its products assist scientific investigations into biological processes and the nature and progress of specific diseases. 

CEO
Kim Kelderman
CEOKim Kelderman
Employees
3,100
Employees3,100
Headquarters
Minneapolis, Minnesota
HeadquartersMinneapolis, Minnesota
Founded
1976
Founded1976
Employees
3,100
Employees3,100

TECH Key Statistics

Market cap
10.23B
Market cap10.23B
Price-Earnings ratio
132.97
Price-Earnings ratio132.97
Dividend yield
0.49%
Dividend yield0.49%
Average volume
1.35M
Average volume1.35M
High today
$66.21
High today$66.21
Low today
$64.95
Low today$64.95
Open price
$65.32
Open price$65.32
Volume
221.98K
Volume221.98K
52 Week high
$79.28
52 Week high$79.28
52 Week low
$46.01
52 Week low$46.01

Stock Snapshot

As of today, Bio-Techne(TECH) shares are valued at $65.65. The company's market cap stands at 10.23B, with a P/E ratio of 132.97 and a dividend yield of 49.2%.

As of 2026-01-09, Bio-Techne(TECH) stock has fluctuated between $64.95 and $66.21. The current price stands at $65.65, placing the stock +1.1% above today's low and -0.9% off the high.

The Bio-Techne(TECH)'s current trading volume is 221.98K, compared to an average daily volume of 1.35M.

In the last year, Bio-Techne(TECH) shares hit a 52-week high of $79.28 and a 52-week low of $46.01.

In the last year, Bio-Techne(TECH) shares hit a 52-week high of $79.28 and a 52-week low of $46.01.

TECH News

TipRanks 4d
Bio-Techne downgraded to In Line from Outperform at Evercore ISI

Evercore ISI downgraded Bio-Techne (TECH) to In Line from Outperform with a price target of $62, down from $68. Claim 70% Off TipRanks This Holiday Season Pub...

Simply Wall St 5d
Should Bio-Techne’s Revenue Miss Raise Doubts About Its Scientific Platform’s Commercial Potential?

In the past quarter, Bio-Techne reported a softer third-quarter performance, with revenues coming in 1.7% below analyst expectations, marking the weakest outcom...

Should Bio-Techne’s Revenue Miss Raise Doubts About Its Scientific Platform’s Commercial Potential?

Analyst ratings

68%

of 19 ratings
Buy
68.4%
Hold
31.6%
Sell
0%

People also own

Based on the portfolios of people who own TECH. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.